The number of tuberculosis cases has risen by 4.5% from 2021; Black and Hispanic patients with COVID-19 were less likely to receive paxlovid in 2022; a new report highlights declines in US cancer death rates between 2015 and 2019.
WHO Declares Rise in Tuberculosis Cases
The number of tuberculosis cases has risen 4.5% from 2021, leading to 10 million worldwide cases and 1.6 million deaths, according to The Associated Press. The numbers came from a new World Health Organization (WHO) report, which also found that the number of people who have been infected with drug-resistant tuberculosis has increased 3.0% since 2020. The WHO said that the COVID-19 pandemic may be to blame, claiming that progress in diagnosis and treating tuberculosis has “slowed, stalled, or reversed.” Tuberculosis is considered the second most deadly infectious disease after COVID-19. Prior to the rise, the WHO reported that the number of newly infected people with tuberculosis fell form 7 million in 2019 to 5.8 million in 2020.
People of Color Less Likely to Receive Paxlovid
According to a new CDC report, patients of color were less likely to receive paxlovid and other COVID-19 treatments in 2022, despite higher rates of COVID-19 hospitalization and deaths compared with White patients. As reported by CNN Health, the new study showed that Black patients with COVID-19 were 36% less likely to be treated with paxlovid compared with White patients, and Hispanic patients were 30% less likely to receive the antiviral pill compared with non-Hispanic patients. The study also found racial disparities in prescribing other treatments such as molnupiravir, remdesivir, and bebtelovimab, but these treatments were less frequently prescribed in general vs paxlovid. The study did not directly assess reasons for these disparities, although the authors noted general disparities in health care access are likely contributing factors.
Downward Trend in US Cancer Deaths
The American Cancer Society’s Annual Report to the Nation on the Status of Cancer showed a downward trend in overall US cancer death rates among men, women, children, teens, and young adults, USA Today reported. Based on pre–COVID-19 data, the report also showed a decline in cancer deaths among every major racial and ethnic group between 2015 and 2019. Cancer deaths decreased by 2.1% for men and women between 2015 and 2019. Additionally, the annual cancer death rate decreased by 2.3% for men and 1.9% for women.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Variable Long COVID Definitions Create Hurdles in Care, Research
August 12th 2025There is a need to consolidate various long COVID definitions to establish a standardized definition that ensures consistent recognition, documentation, diagnosis, and treatment, according to new research.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More